NCT07662720: A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer
- State
- Not started
- Phase
- Phase 1 and Phase 2
- People
- 18 planned
- Started
- 15 Jul 2026
- Primary completion
- 31 Aug 2027
- Arms
- Axelopran in combination with Pembrolizumab in PDL-1 positive patients with HNSCC
- Results
- None posted
- 23 Jun 2026: Trial registered